<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03515187</url>
  </required_header>
  <id_info>
    <org_study_id>LC2016YM017</org_study_id>
    <nct_id>NCT03515187</nct_id>
  </id_info>
  <brief_title>Study on Prevention and Treatment of Dry Eye in Patients Using Glaucoma Drops</brief_title>
  <official_title>A Multicenter Randomized Controlled Trial on Prevention and Treatment of Ocular Surface Injury and Meibomian Gland Dysfunction in Patients Using Anti-Glaucoma Eye Drops</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shenzhen Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shenzhen Hospital of Southern Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multicenter randomized controlled trial on prevention and treatment of ocular surface
      injury and meibomian gland dysfunction in patients using anti-glaucoma eye drops.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. To compare the efficacy of drug therapy (sodium hyaluronate + sodium bromide) and combined
      therapy (combined with meibomian gland massage based on drug therapy) on drug-induced dry eye
      caused by long-term use of anti glaucoma drugs; 2. To evaluate the efficacy of sodium
      hyaluronate in the prevention of ocular surface and meibomian gland dysfunction and
      structural damage in the early stage of patients using anti glaucoma eye drops.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2018</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in Ocular Surface Disease Index (OSDI) score</measure>
    <time_frame>At screening, 1 month and 2 months for treatment.</time_frame>
    <description>Primary indicator</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Tear break up time (TBUT)</measure>
    <time_frame>At screening, 1 month and 2 months for treatment.</time_frame>
    <description>Secondary indicator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in corneal staining scores</measure>
    <time_frame>At screening, 1 month and 2 months for treatment.</time_frame>
    <description>Secondary indicator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in schirmer test</measure>
    <time_frame>At screening, 1 month and 2 months for treatment.</time_frame>
    <description>Secondary indicator</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Intraocular pressure</measure>
    <time_frame>At screening, 1 month and 2 months for treatment.</time_frame>
    <description>Additional indicator</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in number of blocked meibomian glands</measure>
    <time_frame>At screening, 1 month and 2 months for treatment.</time_frame>
    <description>Additional indicator</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Dry Eye</condition>
  <condition>MGD-Meibomian Gland Dysfunction</condition>
  <arm_group>
    <arm_group_label>A1 Medicine treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.3%sodium hyaluronate ophthalmic solution + 0.1 sodium bromide solution, 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A2 Combined treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.3%sodium hyaluronate ophthalmic solution + 0.1 sodium bromide solution，with meibomian gland massage , 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B1 Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B2 Experiment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.3%sodium hyaluronate ophthalmic solution, 12 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.3% sodium hyaluronate ophthalmic solution</intervention_name>
    <description>one to two drops in eye, four times per day</description>
    <arm_group_label>A1 Medicine treatment group</arm_group_label>
    <arm_group_label>A2 Combined treatment group</arm_group_label>
    <arm_group_label>B2 Experiment group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.1% sodium bromide solution</intervention_name>
    <description>one to two drops in eye, twice per day</description>
    <arm_group_label>A1 Medicine treatment group</arm_group_label>
    <arm_group_label>A2 Combined treatment group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Meibomian gland massage</intervention_name>
    <description>Physiotherapy</description>
    <arm_group_label>A2 Combined treatment group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Vehicle</description>
    <arm_group_label>B1 Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-80 years of age, diagnosed with glaucoma, including primary open-angle glaucoma or
             primary angle closure glaucoma, require treatment with anti-glaucoma eye drops.

          -  A group: Patients using glaucoma eye drops longer than 6 months, and in accordance
             with the diagnostic criteria of dry eye:

               1. Subjective symptoms (required): dryness, foreign body sensation, fatigue and
                  discomfort;

               2. The instability of tear film (required): tear break up time (TBUT);

               3. Lacrimal secretion: Schirmer I test;

               4. The ocular surface damage (strengthen diagnosis): fluorescein staining (FL); in
                  the mentioned in ①+②（TBUT≤5s) or ①+②（TBUT≤10s)+③（&lt;10mm）/④（FL+）。

          -  The choice of study eyes: Choose the eye of the patient with low basical intraocular
             pressure, and if the basal intraocular pressure is the same, choose the right eye for
             the study.

          -  Voluntary participation in this clinical study, and signed informed consent.

        Exclusion Criteria:

          -  With metabolic diseases, autoimmune diseases, connective tissue diseases, such as
             diabetes, rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus,
             Sjogren's syndrome eat;

          -  Combined with cerebrovascular, liver, kidney, hematopoietic serious system desease,
             atumor diseases and psychosis.

          -  Using any artificial tears and except any clinical trials of dry eyes within two
             weeks.

          -  With drug therapy, embolization and surgical treatment of dry eyes.

          -  With other eye diseases, such as eyelid defects, hypophasis, pterygium, chronic
             dacryocystitis, trichiasis, corneal lesions.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yingli Li</last_name>
    <role>Study Chair</role>
    <affiliation>Shenzhen Hospital of Southern Medicine University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Min Fu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhejiang Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lang Bai</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nanfang Hospital of Southern Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Guanghua Zhou</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Fifth Affiliated Hospital of Southern Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lei Xi</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guangdong General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xiaolin Zhao</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shenzhen Hospital of Southern Medicine University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wanli Liu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shenzhen Hospital of Southern Medicine University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yan Wang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shenzhen Hospital of Southern Medicine University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lina Chen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shenzhen Hospital of Southern Medicine University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sijing Zhang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shenzhen Hospital of Southern Medicine University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shingle An</last_name>
    <role>Principal Investigator</role>
    <affiliation>Southern Medicine University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Liang Zhang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guangdong General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ting Meng</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhejiang Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yingli Li</last_name>
    <phone>+81-18124783057</phone>
    <email>liyingli333@qq.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xinhua Xi</last_name>
    <phone>+81-18025388978</phone>
    <email>xhxi96@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Yingli Li</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <zip>518110</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Li Yingli</last_name>
      <phone>+81-181-2478-3057</phone>
      <email>liyingli333@qq.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 13, 2017</study_first_submitted>
  <study_first_submitted_qc>April 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 3, 2018</study_first_posted>
  <last_update_submitted>April 22, 2018</last_update_submitted>
  <last_update_submitted_qc>April 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shenzhen Hospital of Southern Medical University</investigator_affiliation>
    <investigator_full_name>Yingli Li</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Dug induced dry eye</keyword>
  <keyword>meibomian gland dysfunction, MGD</keyword>
  <keyword>Sodium hyaluronate ophthalmic solution</keyword>
  <keyword>Sodium bromide hydrate eye drops</keyword>
  <keyword>Meibomian gland massage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Bromides</mesh_term>
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>If we decided to share the individual participants data (IPD), the IPD will be shared with in six months after the clinical trial by loading ResMan(the web-based medical research public management platform— Research manager, ResMan).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

